We are attempting to harness the immune system to cure child leukemia and to use blood-derived stem cells to cure other life threatening childhood diseases.
Currently, blood and marrow transplantation (BMT) is the only successful form of immune therapy for childhood leukemia. Our research group focuses on harnessing the immune forces unleashed by BMT to improve immune therapy for childhood leukemia. By increasing our understanding of these important immune forces, we hope to also improve the ability to provide safe tissue transplants when needed. Lastly, our group is focused on developing approaches to extend the ability to use blood-derived stem cells to regenerate damaged tissues, correct the immune system, and save children and adolescents from life threatening childhood diseases.
Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies
Kirk R. Schultz and Amina Kariminia and Bernard Ng and Sayeh Abdossamadi and Madeline Lauener and Eneida R. Nemecek and Justin T. Wahlstrom and Carrie L. Kitko and Victor A. Lewis and Tal Schechter and David A. Jacobsohn and Andrew C. Harris and Michael A. Pulsipher and Henrique Bittencourt and Sung Won Choi and Emi H. Caywood and Kimberly A. Kasow and Monica Bhatia and Benjamin R. Oshrine and Allyson Flower and Sonali Chaudhury and Donald Coulter and Joseph H. Chewning and Michael Joyce and Sureyya Savasan and Anna B. Pawlowska and Gail C. Megason and David Mitchell and Alexandra C. Cheerva and Anita Lawitschka and Shima Azadpour and Elena Ostroumov and Peter Subrt and Anat Halevy and Sara Mostafavi and Geoffrey D. E. Cuvelier
Access to Hematopoietic Stem Cell Transplantation among Pediatric Patients with Acute Lymphoblastic Leukemia: A Population-Based Analysis
Biology of Blood and Marrow Transplantation
Tony H. Truong and Jason D. Pole and Henrique Bittencourt and Tal Schechter and Geoff D.E. Cuvelier and Kristjan Paulson and Meera Rayar and David Mitchell and Kirk R. Schultz and Debbie O'Shea and Randy Barber and Donna Wall and Lillian Sung
Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis
Biology of Blood and Marrow Transplantation
Jacob Rozmus and Amina Kariminia and Sayeh Abdossamadi and Barry E. Storer and Paul J. Martin and Stephanie J. Lee and Daniel Wolff and Mukta Arora and Corey Cutler and Kirk R. Schultz
The case for plerixafor to replace filgrastim as the optimal agent to mobilize peripheral blood donors for allogeneic hematopoietic cell transplantation
Stephen Couban and Peggy C. Wong and Kirk R. Schultz
EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment
Bone Marrow Transplantation
Helene M. Schoemans and Stephanie J. Lee and James L. Ferrara and Daniel Wolff and John E. Levine and Kirk R. Schultz and Bronwen E. Shaw and Mary E. Flowers and Tapani Ruutu and Hildegard Greinix and Ernst Holler and Grzegorz Basak and Rafael F. Duarte and Steven Z. Pavletic
Influence of Age on Acute and Chronic GVHD in Children Receiving HLA-Identical Sibling BMT for Acute Leukemia: Implications for Prophylaxis.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
New answers to old conundrums: what antibodies, exosomes and inflammasomes bring to the conversation. Canadian National Transplant Research Program international summit report.
Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Outcome of Hematopoietic Cell Transplantation for DNA-Double Strand Breakage Repair Disorders.
Slack J and Albert MH and Balashov D and Belohradsky BH and Bertaina A and Bleesing J and Booth C and Büchner J and Buckley RH and Ouachée-Chardin M and Deripapa E and Drabko K and Eapen M and Feuchtinger T and Finocchi A and Gaspar HB and Ghosh S and Gillio A and Gonzalez-Granado LI and Grunebaum E
Improved survival after acute graft vs host disease diagnosis in the modern era.
Khoury HJ and Wang T and Hemmer MT and Couriel D and Alousi A and Cutler C and Aljurf M and Antin JH and Ayas M and Battiwalla M and Cahn JY and Cairo M and Chen YB and Gale RP and Hashmi S and Hayashi RJ and Jagasia M and Juckett M and Kamble RT and Kharfan-Dabaja M
Erratum to "Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study" [Biol Blood Marrow Transplant 2016;22:1410-1415].
Couban S and Aljurf M and Lachance S and Walker I and Toze C and Rubinger M and Lipton JH and Lee SJ and Szer J and Doocey R and Lewis ID and Huebsch L and Howson-Jan K and Lalancette M and Almohareb F and Chaudhri N and Ivison S and Broady R and Levings M and Fairclough D
The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease.
Cooke KR and Luznik L and Sarantopoulos S and Hakim FT and Jagasia M and Fowler DH and van den Brink MR and Hansen JA and Parkman R and Miklos DB and Martin PJ and Paczesny S and Vogelsang G and Pavletic S and Ritz J and Schultz KR and Blazar BR
Y-box-binding protein 1 contributes to IL-7-mediated survival signaling in B-cell precursor acute lymphoblastic leukemia.
Kariminia A and Ivison SM and Leung VM and Sung S and Couto N and Rozmus J and Rolf N and Narendran A and Dunn SE and Reid GS and Schultz KR
Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study: A Prospective Observational Cohort Study.
McMahon KR and Rod Rassekh S and Schultz KR and Pinsk M and Blydt-Hansen T and Mammen C and Tsuyuki RT and Devarajan P and Cuvelier GD and Mitchell LG and Baruchel S and Palijan A and Carleton BC and Ross CJ and Zappitelli M and Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Group
Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research.
Lazaryan A and Wang T and Spellman SR and Wang HL and Pidala J and Nishihori T and Askar M and Olsson R and Oudshoorn M and Abdel-Azim H and Yong A and Gandhi M and Dandoy C and Savani B and Hale G and Page K and Bitan M and Reshef R and Drobyski W and Marsh SG
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.
Gea-Banacloche J and Komanduri KV and Carpenter P and Paczesny S and Sarantopoulos S and Young JA and El Kassar N and Le RQ and Schultz KR and Griffith LM and Savani BN and Wingard JR
Quantitation of Human Cells that Produce Neutrophils and Platelets in Vivo Obtained from Normal Donors Treated with Granulocyte Colony-Stimulating Factor and/or Plerixafor.
Miller PH and Nakamichi N and Knapp DJ and Rabu G and Schultz KR and Jones DM and Couban S and Eaves CJ
Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study.
Couban S and Aljurf M and Lachance S and Walker I and Toze C and Rubinger M and Lipton JH and Lee SJ and Szer R and Doocey R and Lewis ID and Huebsch L and Howson-Jan K and Lalancette M and Almohareb F and Chaudhri N and Ivison S and Broady R and Levings M and Fairclough D
Successful clinical treatment and functional immunological normalization of human MALT1 deficiency following hematopoietic stem cell transplantation.
Rozmus J and McDonald R and Fung SY and Del Bel KL and Roden J and Senger C and Schultz KR and McKinnon ML and Davis J and Turvey SE
Exome Sequencing and the Management of Neurometabolic Disorders.
Tarailo-Graovac M and Shyr C and Ross CJ and Horvath GA and Salvarinova R and Ye XC and Zhang LH and Bhavsar AP and Lee JJ and Drögemöller BI and Abdelsayed M and Alfadhel M and Armstrong L and Baumgartner MR and Burda P and Connolly MB and Cameron J and Demos M and Dewan T and Dionne J
Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells.
Kariminia A and Holtan SG and Ivison S and Rozmus J and Hebert MJ and Martin PJ and Lee SJ and Wolff D and Subrt P and Abdossamadi S and Sung S and Storek J and Levings M and Aljurf M and Arora M and Cutler C and Gallagher G and Kuruvilla J and Lipton J and Nevill TJ
Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions.
Kumar R and Kimura F and Ahn KW and Hu ZH and Kuwatsuka Y and Klein JP and Pasquini M and Miyamura K and Kato K and Yoshimi A and Inamoto Y and Ichinohe T and Wood WA and Wirk B and Seftel M and Rowlings P and Marks DI and Schultz KR and Gupta V and Dedeken L
Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial.
Walker I and Panzarella T and Couban S and Couture F and Devins G and Elemary M and Gallagher G and Kerr H and Kuruvilla J and Lee SJ and Moore J and Nevill T and Popradi G and Roy J and Schultz KR and Szwajcer D and Toze C and Foley R and Canadian Blood and Marrow Transplant Group
Pediatric chronic myeloid leukemia is a unique disease that requires a different approach.
Hijiya N and Schultz KR and Metzler M and Millot F and Suttorp M
In Vivo T Cell Depletion with Myeloablative Regimens on Outcomes after Cord Blood Transplantation for Acute Lymphoblastic Leukemia in Children.
Ponce DM and Eapen M and Sparapani R and O'Brien TA and Chan KW and Chen J and Craddock J and Schultz KR and Wagner JE and Perales MA and Barker JN
Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure.
Ayas M and Eapen M and Le-Rademacher J and Carreras J and Abdel-Azim H and Alter BP and Anderlini P and Battiwalla M and Bierings M and Buchbinder DK and Bonfim C and Camitta BM and Fasth AL and Gale RP and Lee MA and Lund TC and Myers KC and Olsson RF and Page KM and Prestidge TD
Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?
Pulsipher MA and Langholz B and Wall DA and Schultz KR and Bunin N and Carroll W and Raetz E and Gardner S and Goyal RK and Gastier-Foster J and Borowitz M and Teachey D and Grupp SA
Heterodimer-specific TLR2 stimulation results in divergent functional outcomes in B-cell precursor acute lymphoblastic leukemia.
Rolf N and Kariminia A and Ivison S and Reid GS and Schultz KR
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report.
Carpenter PA and Kitko CL and Elad S and Flowers ME and Gea-Banacloche JC and Halter JP and Hoodin F and Johnston L and Lawitschka A and McDonald GB and Opipari AW and Savani BN and Schultz KR and Smith SR and Syrjala KL and Treister N and Vogelsang GB and Williams KM and Pavletic SZ and Martin PJ
Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802.
Holtan SG and Verneris MR and Schultz KR and Newell LF and Meyers G and He F and DeFor TE and Vercellotti GM and Slungaard A and MacMillan ML and Cooley SA and Blazar BR and Panoskaltsis-Mortari A and Weisdorf DJ
Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.
Lee SJ and Wolff D and Kitko C and Koreth J and Inamoto Y and Jagasia M and Pidala J and Olivieri A and Martin PJ and Przepiorka D and Pusic I and Dignan F and Mitchell SA and Lawitschka A and Jacobsohn D and Hall AM and Flowers ME and Schultz KR and Vogelsang G and Pavletic S
IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.
Pulsipher MA and Carlson C and Langholz B and Wall DA and Schultz KR and Bunin N and Kirsch I and Gastier-Foster JM and Borowitz M and Desmarais C and Williamson D and Kalos M and Grupp SA
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.
Paczesny S and Hakim FT and Pidala J and Cooke KR and Lathrop J and Griffith LM and Hansen J and Jagasia M and Miklos D and Pavletic S and Parkman R and Russek-Cohen E and Flowers ME and Lee S and Martin P and Vogelsang G and Walton M and Schultz KR
NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report.
Shulman HM and Cardona DM and Greenson JK and Hingorani S and Horn T and Huber E and Kreft A and Longerich T and Morton T and Myerson D and Prieto VG and Rosenberg A and Treister N and Washington K and Ziemer M and Pavletic SZ and Lee SJ and Flowers ME and Schultz KR and Jagasia M
Hematopoietic Cell Transplantation and Cellular Therapeutics in the Treatment of Childhood Malignancies
Pediatric Clinics of North America
Kanwaldeep Mallhi and Lawrence G. Lum and Kirk R. Schultz and Maxim Yankelevich
Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.
Arai S and Arora M and Wang T and Spellman SR and He W and Couriel DR and Urbano-Ispizua A and Cutler CS and Bacigalupo AA and Battiwalla M and Flowers ME and Juckett MB and Lee SJ and Loren AW and Klumpp TR and Prockup SE and Ringdén OT and Savani BN and Socié G and Schultz KR
TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521).
Yanik GA and Grupp SA and Pulsipher MA and Levine JE and Schultz KR and Wall DA and Langholz B and Dvorak CC and Alangaden K and Goyal RK and White ES and Collura JM and Skeens MA and Eid S and Pierce EM and Cooke KR
Hematopoietic Stem Cell Transplantation for X-Linked Thrombocytopenia With Mutations in the WAS gene.
Oshima K and Imai K and Albert MH and Bittner TC and Strauss G and Filipovich AH and Morio T and Kapoor N and Dalal J and Schultz KR and Casper JT and Notarangelo LD and Ochs HD and Nonoyama S
One-unit versus two-unit cord-blood transplantation for hematologic cancers.
Wagner JE and Eapen M and Carter S and Wang Y and Schultz KR and Wall DA and Bunin N and Delaney C and Haut P and Margolis D and Peres E and Verneris MR and Walters M and Horowitz MM and Kurtzberg J and Blood and Marrow Transplant Clinical Trials Network
Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation.
Pidala J and Lee SJ and Ahn KW and Spellman S and Wang HL and Aljurf M and Askar M and Dehn J and Fernandez Viña M and Gratwohl A and Gupta V and Hanna R and Horowitz MM and Hurley CK and Inamoto Y and Kassim AA and Nishihori T and Mueller C and Oudshoorn M and Petersdorf EW
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.
Schultz KR and Carroll A and Heerema NA and Bowman WP and Aledo A and Slayton WB and Sather H and Devidas M and Zheng HW and Davies SM and Gaynon PS and Trigg M and Rutledge R and Jorstad D and Winick N and Borowitz MJ and Hunger SP and Carroll WL and Camitta B and Children’s Oncology Group
Combined immunodeficiency associated with homozygous MALT1 mutations.
McKinnon ML and Rozmus J and Fung SY and Hirschfeld AF and Del Bel KL and Thomas L and Marr N and Martin SD and Marwaha AK and Priatel JJ and Tan R and Senger C and Tsang A and Prendiville J and Junker AK and Seear M and Schultz KR and Sly LM and Holt RA and Patel MS
Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children's Oncology Group Study AALL0031.
Schultz KR and Devidas M and Bowman WP and Aledo A and Slayton WB and Sather H and Zheng HW and Davies SM and Gaynon PS and Trigg M and Rutledge R and Jorstad D and Carroll AJ and Heerema N and Winick N and Borowitz MJ and Hunger SP and Carroll WL and Camitta B and Children’s Oncology Group
The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.
Pulsipher MA and Langholz B and Wall DA and Schultz KR and Bunin N and Carroll WL and Raetz E and Gardner S and Gastier-Foster JM and Howrie D and Goyal RK and Douglas JG and Borowitz M and Barnes Y and Teachey DT and Taylor C and Grupp SA
Paroxysmal nocturnal haemoglobinuria phenotype cells and leucocyte subset telomere length in childhood acquired aplastic anaemia.
Tutelman PR and Aubert G and Milner RA and Dalal BI and Schultz KR and Deyell RJ
Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens.
Bitan M and He W and Zhang MJ and Abdel-Azim H and Ayas MF and Bielorai B and Carpenter PA and Cairo MS and Diaz MA and Horan JT and Jodele S and Kitko CL and Schultz KR and Kletzel M and Kasow KA and Lehmann LE and Mehta PA and Shah N and Pulsipher MA and Prestidge T
Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation.
Fernandez-Viña MA and Wang T and Lee SJ and Haagenson M and Aljurf M and Askar M and Battiwalla M and Baxter-Lowe LA and Gajewski J and Jakubowski AA and Marino S and Oudshoorn M and Marsh SG and Petersdorf EW and Schultz K and Turner EV and Waller EK and Woolfrey A and Umejiego J and Spellman SR
Severe combined immunodeficiency (SCID) in Canadian children: a national surveillance study.
Rozmus J and Junker A and Thibodeau ML and Grenier D and Turvey SE and Yacoub W and Embree J and Haddad E and Langley JM and Ramsingh RM and Singh VA and Long R and Schultz KR
Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality.
Pidala J and Wang T and Haagenson M and Spellman SR and Askar M and Battiwalla M and Baxter-Lowe LA and Bitan M and Fernandez-Viña M and Gandhi M and Jakubowski AA and Maiers M and Marino SR and Marsh SG and Oudshoorn M and Palmer J and Prasad VK and Reddy V and Ringden O and Saber W
Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft versus host disease consortium study.
Arora M and Pidala J and Cutler CS and Chai X and Kurland B and Jacobsohn DA and Pavletic SZ and Palmer J and Vogelsang G and Jagasia M and Schultz K and Lee SJ
Prediction of area under the cyclosporine concentration versus time curve in children undergoing hematopoietic stem cell transplantation.
Dupuis LL and Seto W and Teuffel O and Gibson P and Schultz KR and Doyle JD and Gassas A and Egeler RM and Sung L and Schechter T
Excess of veno-occlusive disease in a randomized clinical trial on a higher trigger for red blood cell transfusion after bone marrow transplantation: a canadian blood and marrow transplant group trial.
Robitaille N and Lacroix J and Alexandrov L and Clayton L and Cortier M and Schultz KR and Bittencourt H and Duval M
Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease.
Palmer JM and Lee SJ and Chai X and Storer BE and Flowers ME and Schultz KR and Inamoto Y and Cutler C and Pidala J and Arora M and Jacobsohn DA and Carpenter PA and Pavletic SZ and Martin PJ
HLA-matched sibling transplantation for severe aplastic anemia: impact of HLA DR15 antigen status on engraftment, graft-versus-host disease, and overall survival.
Battiwalla M and Wang T and Carreras J and Deeg HJ and Ayas M and Bajwa RP and George B and Gupta V and Pasquini R and Schrezenmeier H and Passweg JR and Schultz KR and Eapen M
Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).
Kamani NR and Walters MC and Carter S and Aquino V and Brochstein JA and Chaudhury S and Eapen M and Freed BM and Grimley M and Levine JE and Logan B and Moore T and Panepinto J and Parikh S and Pulsipher MA and Sande J and Schultz KR and Spellman S and Shenoy S
Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study.
Chang BH and Willis SG and Stork L and Hunger SP and Carroll WL and Camitta BM and Winick NJ and Druker BJ and Schultz KR
Inhibition of cathepsin S reduces allogeneic T cell priming but not graft-versus-host disease against minor histocompatibility antigens.
Fujii H and Ivison SM and Shimizu H and Kajiwara R and Kariminia A and Yan M and Dutz JP and Schultz KR
Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study.
Gilman AL and Schultz KR and Goldman FD and Sale GE and Krailo MD and Chen Z and Langholz B and Jacobsohn DA and Chan KW and Ryan RE and Kellick M and Neudorf SM and Godder K and Sandler ES and Sahdev I and Grupp SA and Sanders JE and Wall DA
Early and late extensive chronic graft-versus-host disease in children is characterized by different Th1/Th2 cytokine profiles: findings of the Children's Oncology Group Study ASCT0031.
Rozmus J and Schultz KR and Wynne K and Kariminia A and Satyanarayana P and Krailo M and Grupp SA and Gilman AL and Goldman FD
Immunosuppressive Therapy Without Hematopoietic Growth Factor Exposure in Pediatric Acquired Aplastic Anemia
Pediatric Hematology and Oncology
Rebecca J. Deyell and Evan B. Shereck and Ruth A. Milner and Kirk R. Schultz
Unrelated donor bone marrow transplantation for myelodysplastic syndrome in children.
Woodard P and Carpenter PA and Davies SM and Gross TG and He W and Zhang MJ and Horn BN and Margolis DA and Perentesis JP and Sanders JE and Schultz KR and Seber A and Woods WG and Eapen M
Controversies in the Treatment of CML in Children and Adolescents: TKIs versus BMT?
Biology of Blood and Marrow Transplantation
Meinolf Suttorp and Isaac Yaniv and Kirk R. Schultz
Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors.
Shaw PJ and Kan F and Woo Ahn K and Spellman SR and Aljurf M and Ayas M and Burke M and Cairo MS and Chen AR and Davies SM and Frangoul H and Gajewski J and Gale RP and Godder K and Hale GA and Heemskerk MB and Horan J and Kamani N and Kasow KA and Chan KW
Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children's Oncology Groups Study, ASCT0031.
Cuvelier GD and Kariminia A and Fujii H and Aslanian S and Wall D and Goldman F and Grupp SA and Dunn SE and Krailo M and Shapiro LH and Gilman A and Schultz KR
Advancement of pediatric blood and marrow transplantation research in North America: priorities of the Pediatric Blood and Marrow Transplant Consortium.
Pulsipher MA and Horwitz EM and Haight AE and Kadota R and Chen AR and Frangoul H and Cooper LJ and Jacobsohn DA and Goyal RK and Mitchell D and Nieder ML and Yanik G and Cowan MJ and Soni S and Gardner S and Shenoy S and Taylor D and Cairo M and Schultz KR
Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.
Duval M and Klein JP and He W and Cahn JY and Cairo M and Camitta BM and Kamble R and Copelan E and de Lima M and Gupta V and Keating A and Lazarus HM and Litzow MR and Marks DI and Maziarz RT and Rizzieri DA and Schiller G and Schultz KR and Tallman MS and Weisdorf D
Tumor necrosis factor-alpha gene polymorphisms are associated with severity of acute graft-versus-host disease following matched unrelated donor bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium study.
Goyal RK and Lin Y and Schultz KR and Ferrell RE and Kim Y and Fairfull L and Livote E and Yanik G and Atlas M
Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss.
Medyouf H and Gao X and Armstrong F and Gusscott S and Liu Q and Gedman AL and Matherly LH and Schultz KR and Pflumio F and You MJ and Weng AP
Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management.
Griffith LM and Cowan MJ and Notarangelo LD and Puck JM and Buckley RH and Candotti F and Conley ME and Fleisher TA and Gaspar HB and Kohn DB and Ochs HD and O'Reilly RJ and Rizzo JD and Roifman CM and Small TN and Shearer WT and Workshop Participants
Impact of conditioning regimen in allogeneic hematopoetic stem cell transplantation for children with acute myelogenous leukemia beyond first complete remission: a pediatric blood and marrow transplant consortium (PBMTC) study.
Sisler IY and Koehler E and Koyama T and Domm JA and Ryan R and Levine JE and Pulsipher MA and Haut PR and Schultz KR and Taylor DS and Frangoul HA
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.
Schultz KR and Bowman WP and Aledo A and Slayton WB and Sather H and Devidas M and Wang C and Davies SM and Gaynon PS and Trigg M and Rutledge R and Burden L and Jorstad D and Carroll A and Heerema NA and Winick N and Borowitz MJ and Hunger SP and Carroll WL and Camitta B
Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study.
Jacobsohn DA and Gilman AL and Rademaker A and Browning B and Grimley M and Lehmann L and Nemecek ER and Thormann K and Schultz KR and Vogelsang GB
Intracranial calcification after cord blood neonatal transplantation for krabbe disease.
Lehman AM and Schultz KR and Poskitt K and Bjornson B and Keyes R and Waters PJ and Clarke LA and Everett R and McConnell D and Stockler S
The long-term outcomes of presymptomatic infants transplanted for Krabbe disease: report of the workshop held on July 11 and 12, 2008, Holiday Valley, New York.
Duffner PK and Caviness VS and Erbe RW and Patterson MC and Schultz KR and Wenger DA and Whitley C
Optimizing outcomes of hematopoietic stem cell transplantation for severe combined immunodeficiency.
Cuvelier GD and Schultz KR and Davis J and Hirschfeld AF and Junker AK and Tan R and Turvey SE
44. Outcomes of children transplanted for Krabbe disease
Molecular Genetics and Metabolism
Patricia Duffner and Rajinder Bawa and Martin Champagne and Lawrence Charnas and Morris Kletzl and Daniel Pietryga and Kirk Schultz and Brandon Triplett
Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs.
Griffith LM and Cowan MJ and Kohn DB and Notarangelo LD and Puck JM and Schultz KR and Buckley RH and Eapen M and Kamani NR and O'Reilly RJ and Parkman R and Roifman CM and Sullivan KE and Filipovich AH and Fleisher TA and Shearer WT
Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical Trials.
Griffith LM and Pavletic SZ and Lee SJ and Martin PJ and Schultz KR and Vogelsang GB
Detection of WT1-specific T cells in paediatric acute lymphoblastic leukaemia patients in first remission.
Barbaric D and Corthals SL and Jastaniah WA and Asalanian S and Shimizu H and Reid GS and Schultz KR
Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group.
Fujii H and Cuvelier G and She K and Aslanian S and Shimizu H and Kariminia A and Krailo M and Chen Z and McMaster R and Bergman A and Goldman F and Grupp SA and Wall DA and Gilman AL and Schultz KR
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.
Bond M and Bernstein ML and Pappo A and Schultz KR and Krailo M and Blaney SM and Adamson PC
Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease.
She K and Gilman AL and Aslanian S and Shimizu H and Krailo M and Chen Z and Reid GS and Wall D and Goldman F and Schultz KR
In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides.
Fujii H and Trudeau JD and Teachey DT and Fish JD and Grupp SA and Schultz KR and Reid GS
Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: A children's oncology group study report.
Satwani P and Sather H and Ozkaynak F and Heerema NA and Schultz KR and Sanders J and Kersey J and Davenport V and Trigg M and Cairo MS
Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).
Schultz KR and Pullen DJ and Sather HN and Shuster JJ and Devidas M and Borowitz MJ and Carroll AJ and Heerema NA and Rubnitz JE and Loh ML and Raetz EA and Winick NJ and Hunger SP and Carroll WL and Gaynon PS and Camitta BM
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report.
Martin PJ and Weisdorf D and Przepiorka D and Hirschfeld S and Farrell A and Rizzo JD and Foley R and Socie G and Carter S and Couriel D and Schultz KR and Flowers ME and Filipovich AH and Saliba R and Vogelsang GB and Pavletic SZ and Lee SJ and Design of Clinical Trials Working Group
HLA-DM expression is elevated in ETV6–AML1 translocation-positive pediatric acute lymphoblastic leukemia
Wasil A. Jastaniah and Angela J. Alessandri and Gregor S.D. Reid and Kirk R. Schultz
Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee.
Grupp SA and Frangoul H and Wall D and Pulsipher MA and Levine JE and Schultz KR
Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report.
Couriel D and Carpenter PA and Cutler C and Bolaños-Meade J and Treister NS and Gea-Banacloche J and Shaughnessy P and Hymes S and Kim S and Wayne AS and Chien JW and Neumann J and Mitchell S and Syrjala K and Moravec CK and Abramovitz L and Liebermann J and Berger A and Gerber L and Schubert M
A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission.
Marks DI and Forman SJ and Blume KG and Pérez WS and Weisdorf DJ and Keating A and Gale RP and Cairo MS and Copelan EA and Horan JT and Lazarus HM and Litzow MR and McCarthy PL and Schultz KR and Smith DD and Trigg ME and Zhang MJ and Horowitz MM
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report.
Pavletic SZ and Martin P and Lee SJ and Mitchell S and Jacobsohn D and Cowen EW and Turner ML and Akpek G and Gilman A and McDonald G and Schubert M and Berger A and Bross P and Chien JW and Couriel D and Dunn JP and Fall-Dickson J and Farrell A and Flowers ME and Greinix H
Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report.
Schultz KR and Miklos DB and Fowler D and Cooke K and Shizuru J and Zorn E and Holler E and Ferrara J and Shulman H and Lee SJ and Martin P and Filipovich AH and Flowers ME and Weisdorf D and Couriel D and Lachenbruch PA and Mittleman B and Vogelsang GB and Pavletic SZ
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report.
Shulman HM and Kleiner D and Lee SJ and Morton T and Pavletic SZ and Farmer E and Moresi JM and Greenson J and Janin A and Martin PJ and McDonald G and Flowers ME and Turner M and Atkinson J and Lefkowitch J and Washington MK and Prieto VG and Kim SK and Argenyi Z and Diwan AH
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.
Filipovich AH and Weisdorf D and Pavletic S and Socie G and Wingard JR and Lee SJ and Martin P and Chien J and Przepiorka D and Couriel D and Cowen EW and Dinndorf P and Farrell A and Hartzman R and Henslee-Downey J and Jacobsohn D and McDonald G and Mittleman B and Rizzo JD and Robinson M
Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States.
Baker KS and Loberiza FR and Yu H and Cairo MS and Bolwell BJ and Bujan-Boza WA and Camitta BM and Garcia JJ and Ho WG and Liesveld JL and Maharaj D and Marks DI and Schultz KR and Wiernik P and Zander AR and Horowitz MM and Keating A and Weisdorf DJ
Increased TLR9 Responses in B Cells at the Onset of Chronic GVHD
Journal of Pediatric Hematology/Oncology
Kevin She and Soudabeh Aslanian and Hiromi Shimizu and Andrew L Gilman and Kirk R Schultz
Inhibition of Cathepsin S Alters the T Cell Response to Minor Histocompatibility Antigens
Journal of Pediatric Hematology/Oncology
Hisaki Fujii and Hiromi Shimizu and Zhijuan Luo and Kirk R Schultz
High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia: a Children's Oncology Group (COG) initiative.
Sutcliffe MJ and Shuster JJ and Sather HN and Camitta BM and Pullen J and Schultz KR and Borowitz MJ and Gaynon PS and Carroll AJ and Heerema NA
CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response.
Reid GS and She K and Terrett L and Food MR and Trudeau JD and Schultz KR
The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML).
Hasle H and Baumann I and Bergsträsser E and Fenu S and Fischer A and Kardos G and Kerndrup G and Locatelli F and Rogge T and Schultz KR and Starý J and Trebo M and van den Heuvel-Eibrink MM and Harbott J and Nöllke P and Niemeyer CM and European Working Group on childhood MDS
Coronary vessel involvement by chronic graft-versus-host disease presenting as sudden cardiac death.
Prevost D and Taylor G and Sanatani S and Schultz KR
Differential effects of granulocyte colony-stimulating factor on marrow- and blood-derived hematopoietic and immune cell populations in healthy human donors.
Shier LR and Schultz KR and Imren S and Regan J and Issekutz A and Sadek I and Gilman A and Luo Z and Panzarella T and Eaves CJ and Couban S
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.
Cutler CS and Lee SJ and Greenberg P and Deeg HJ and Pérez WS and Anasetti C and Bolwell BJ and Cairo MS and Gale RP and Klein JP and Lazarus HM and Liesveld JL and McCarthy PL and Milone GA and Rizzo JD and Schultz KR and Trigg ME and Keating A and Weisdorf DJ and Antin JH
Expression of the adaptor protein BLNK/SLP-65 in childhood acute lymphoblastic leukemia.
Imai C and Ross ME and Reid G and Coustan-Smith E and Schultz KR and Pui CH and Downing JR and Campana D
Canadian multicenter pilot trial of haploidentical donor transplantation.
Walker I and Shehata N and Cantin G and Couture F and Dhédin N and Barty R and Foley R and Sutherland RD and Sigouin C and Schultz KR and Mitchell D and Canadian Blood and Marrow Transplant Group
Altered patterns of T cell cytokine production induced by relapsed pre-B ALL cells.
Reid GS and Terrett L and Alessandri AJ and Grubb S and Stork L and Seibel N and Gaynon P and Schultz KR
Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7.
Kardos G and Baumann I and Passmore SJ and Locatelli F and Hasle H and Schultz KR and Starý J and Schmitt-Graeff A and Fischer A and Harbott J and Chessells JM and Hann I and Fenu S and Rajnoldi AC and Kerndrup G and Van Wering E and Rogge T and Nollke P and Niemeyer CM
Non-resectable congenital tumors with the ETV6-NTRK3 gene fusion are highly responsive to chemotherapy.
McCahon E and Sorensen PH and Davis JH and Rogers PC and Schultz KR
The impact of Asian descent on the incidence of acquired severe aplastic anaemia in children.
McCahon E and Tang K and Rogers PC and McBride ML and Schultz KR
Evaluation for synergistic suppression of T cell responses to minor histocompatibility antigens by chloroquine in combination with tacrolimus and a rapamycin derivative, SDZ-RAD.
Hsiao CC and Su WN and Forooghian F and Bader S and Rempel J and HayGlass KT and Gilman A and Schultz KR
Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission.
Litzow MR and Pérez WS and Klein JP and Bolwell BJ and Camitta B and Copelan EA and Gale RP and Giralt SA and Keating A and Lazarus HM and Marks DI and McCarthy PL and Miller CB and Milone G and Prentice HG and Russell JA and Schultz KR and Trigg ME and Weisdorf DJ and Horowitz MM
Differential killing of pre-B acute lymphoblastic leukaemia cells by activated NK cells and the NK-92 ci cell line.
Reid GS and Bharya S and Klingemann HG and Schultz KR
ETV6 (TEL)-AML1 pre-B acute lymphoblastic leukaemia cells are associated with a distinct antigen-presenting phenotype.
Alessandri AJ and Reid GS and Bader SA and Massing BG and Sorensen PH and Schultz KR
Chloroquine prevention of murine MHC-disparate acute graft-versus-host disease correlates with inhibition of splenic response to CpG oligodeoxynucleotides and alterations in T-cell cytokine production.
Schultz KR and Su WN and Hsiao CC and Doho G and Jevon G and Bader S and MacFarlane DE and Gilman AL
Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes.
Weisdorf D and Bishop M and Dharan B and Bolwell B and Cahn JY and Cairo M and Giralt S and Klein J and Lazarus H and Litzow M and Marks D and McCarthy P and Miller C and Milone G and Russell J and Schultz KR and Sierra J and Wiernik P and Keating A and Loberiza F
Absence of t(12;15) associatedETV6-NTRK3 fusion transcripts in pediatric acute leukemias
Medical and Pediatric Oncology
Angela J. Alessandri and Stevan R. Knezevich and Joan A. Mathers and Kirk R. Schultz and Poul H.B. Sorensen
Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
Schultz KR and Nevill TJ and Balshaw RF and Toze CL and Corr T and Currie CJ and Strong DK and Keown PA
Age is the major determinant of recurrence in pediatric differentiated thyroid carcinoma
Medical and Pediatric Oncology
Angela J. Alessandri and Karen J. Goddard and Geoffrey K. Blair and Chris J.H. Fryer and Kirk R. Schultz
Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia.
Barrett AJ and Ringdén O and Zhang MJ and Bashey A and Cahn JY and Cairo MS and Gale RP and Gratwohl A and Locatelli F and Martino R and Schultz KR and Tiberghien P
Age is the major determinant of recurrence in pediatric differentiated thyroid carcinoma
Medical and Pediatric Oncology
Angela J. Alessandri and Karen J. Goddard and Geoffrey K. Blair and Chris J.H. Fryer and Kirk R. Schultz
Hydroxychloroquine for the treatment of chronic graft-versus-host disease.
Gilman AL and Chan KW and Mogul A and Morris C and Goldman FD and Boyer M and Cirenza E and Mazumder A and Gehan E and Cahill R and Frankel S and Schultz K
A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada.
Hasle H and Wadsworth LD and Massing BG and McBride M and Schultz KR
Misleading leads: Bone pain caused by isolated paraspinal extramedullary relapse of childhood acute lymphoblastic leukemia.
Alessandri AJ and Pritchard SL and Massing BG and Sargent MA and Theissen P and Schultz KR
The pharmacokinetics of oral cyclosporin A (Neoral) during the first month after bone marrow transplantation.
Schultz KR and Nevill TJ and Toze CL and Corr T and Currie C and Strong DK and Keown PA
Immune suppression by lysosomotropic amines and cyclosporine on T-cell responses to minor and major histocompatibility antigens: does synergy exist?
Schultz KR and Bader S and Nelson D and Wang MD and HayGlass KT
Importance of the day 7 bone marrow biopsy as a prognostic measure of the outcome in children with acute lymphoblastic leukemia.
Schultz KR and Massing B and Spinelli JJ and Gaynon PS and Wadsworth L
Treatment of familial erythrophagocytic lymphohistiocytosis with cyclosporine A
The Journal of Pediatrics
Esteban M. Abella and John Artrip and Kirk Schultz and Yaddanapudi Ravindranath
The Lysosomotropic Amines, Chloroquine and Hydroxychloroquine: A Potentially Novel Therapy for Graft-Versus-Host Disease
Leukemia & Lymphoma
Kirk R. Schultz and Andrew L. Gilman
Immunosuppressive therapy: a potential alternative to bone marrow transplantation as initial therapy for acquired severe aplastic anemia in childhood?
Lawlor ER and Anderson RA and Davis JH and Fryer CJ and Pritchard SL and Rogers PC and Wu JK and Schultz KR
Synergy between lysosomotropic amines and cyclosporin A on human T cell responses to an exogenous protein antigen, tetanus toxoid.
Schultz KR and Nelson D and Bader S
Genetic heterogeneity in familial dilated cardiomyopathy.
Schultz KR and Gajarski RJ and Pignatelli R and Goytia V and Roberts R and Bachinski L and Towbin JA
Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease.
Schultz KR and Bader S and Paquet J and Li W
Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease.
Schultz KR and Paquet J and Bader S and HayGlass KT
Association of gastroesophageal reflux with obstructive lung disease in children after allogeneic bone marrow transplantation.
Schultz KR and Fernandez CV and Israel DM and Magee F and Wensley D and Sargent MA and Abella E and Karanes C
Cyclosporin A therapy of immune-mediated thrombocytopenia in children.
Schultz KR and Strahlendorf C and Warrier I and Ravindranath Y
Obstructive lung disease in children after allogeneic bone marrow transplantation.
Schultz KR and Green GJ and Wensley D and Sargent MA and Magee JF and Spinelli JJ and Pritchard S and Davis JH and Rogers PC and Chan KW
Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens.
Schultz KR and Ratanatharathorn V and Abella E and Eisenbrey AB and Karanes C and Lum LG and de Planque MM and Uberti JP and Ravindranath Y and Sensenbrenner LL
Coactivation with anti-CD28 monoclonal antibody enhances anti-CD3 monoclonal antibody-induced proliferation and IL-2 synthesis in T cells from autologous bone marrow transplant recipients.
Lum LG and Joshi ID and Galoforo SC and Abella E and Karanes C and Ratanatharathorn V and Schultz KR and Uberti JP and Sensenbrenner LL and Ledbetter JA
An increased relative frequency of retinoblastoma at a rural regional referral hospital in Miraj, Maharashtra, India
Kirk R. Schultz and Shashi Ranade and Joseph P. Neglia and Yaddanapudi Ravindranath
Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes.
Ratanatharathorn V and Karanes C and Uberti J and Lum LG and de Planque MM and Schultz KR and Cronin S and Dan ME and Mohamed A and Hussein M
Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC).
Ratanatharathorn V and Karanes C and Lum LG and Uberti J and Dan ME and de Planque MM and Schultz KR and Cronin S and Leisz MC and Mohamed A
Effect of interleukin-2 on biodistribution of monoclonal antibody in tumor and normal tissues in mice bearing SL-2 thymoma.
Schultz KR and Badger CC and Dombi GW and Greenberg PD and Bernstein ID
Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
Schultz KR and Klarnet JP and Peace DJ and Cheever MA and Badger CC and Bernstein ID and Greenberg PD
The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia.
Schultz KR and Klarnet JP and Gieni RS and HayGlass KT and Greenberg PD
IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
Peace DJ and Kern DE and Schultz KR and Greenberg PD and Cheever MA
My work has evaluated clinically driven issues related to hematopoietic cell transplantation. Clinical investigations have focused on age-related factors affecting graft-versus-host disease (GVHD), graft-failure and graft-versus-leukemia (GVL). Laboratory investigations have used pre-clinical models and the performance of correlative studies in humans to investigate the mechanisms of GVHD and GVL and to develop experimental approaches to modulate these phenomena.
Our laboratory has evaluated the hypothesis that manipulation of MHC class II antigen presentation can alter T cell responses to endogenous antigens. We have investigated the importance of two MHC class II antigen presenting cells in vivo, B cells and dendritic cells, for T cell priming responses to leukemia, and minor histocompatibility antigens (MiHC). We have also investigated whether inhibition of MHC class II antigen presentation by lysosomotropic agents such as chloroquine can inhibit T cell responses to MiHC and development of GVHD. We have translated these pre-clinical observations into clinical studies. We have been one of the first groups to identify chronic GVHD biomarkers in children.
We are also investigating approaches to increasing T cell responses to leukemia by immunization approaches focused on overcoming defects in antigen presentation of endogenous antigens that are either specific to the malignancy or over-expressed in the malignancy. We have focused on the ability of all cells to act as antigen presenting cells and utilizing TLR agonists that affect both leukemic cell immunogenicity and anti-leukemia immune response.
I have been very involved in developing clinical trials focused on improving therapy for GVHD and Acute Lymphoblastic Leukemia. I am a prominent member of clinical co-operative groups including the Children’s Oncology Group (COG), Canadian Blood and Marrow Transplantation Group (CBMTG), Chronic GHVD Consensus Group (NIH sponsored), and C17 (a Canadian pediatric oncology research group). I am currently the group chair of the Pediatric BMT Consortium, a cooperative group that includes over 85 pediatric BMT centers in North America, Australia and New Zealand.Honours & Awards
Election to Fellowship in the Canadian Academy of Health Sciences (CAHS) – 2014
Canadian National Transplant Research Program, CIHR and Genome BC – 2013
Geoffrey L. Hammond Lectureship Award, CFRI Member Recognition Awards – 2013Research Group Members
Sayeh Abdossamadi, Research Assistant
Mariam Arandi , Data management trainee
Rupa Aulakh, Clinical Research Associate
Shima Azad Pour, Visitor Scientist
Victoria Chong, Trainee
Nancy Cooper, Clinical Research Associate
Cecilia Crosby, Clinical Research Associate
Jessica Davis, Clinical Trials Unit Manager
Colleen Fitzgerald, Research Services Manager
Fraser Jang-Milligan, Medical Student
Colleen Jantzen, Research Asst/Tech 3
Il Jo, Visiting Researcher Volunteer, MD
Hina Johnstone, Research and Facilitation:Research and Facilitation
Amina Kariminia, Scientist (Schultz) & TAB Lab manager
Rachel Li, Clinical Fellow
Alecia Lim, Assistant Clinical Trials Unit Manager
Alana Nemetchek, Clinical Research Associate
Elena Ostroumov, Clinical Research Manager
Judith Portner, Research assistant
Rina Saguin, Clinical Research Associate Coordinator
Sally Samaan, Clinical Research Associate
Ellie Wong, Clinical Research Associate
Alan Zhang, Summer Student
Preventing a devastating complication of lifesaving transplants: Two types of immune cells reduce the risk of graft versus host disease
Right now, 25% of children who survive blood and marrow transplants go on to develop chronic graft-versus-host disease (cGvHD), an incurable condition that can cause lifelong pain and disability.